Medscape

Medscape is a reputable source of medical news and information for healthcare professionals. The site provides up-to-date information on the latest research, drugs, treatments, and medical conferences. While there are occasional contradictions, conflicts of interest, and instances of deceptive practices, these are generally rare and not a consistent issue. The site has a slight bias towards providing accurate and up-to-date information for its audience.

82%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This news site has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on its reporting.

Bias

85%

Examples:

  • The site has a slight bias towards providing up-to-date and accurate information for healthcare professionals.

Conflicts of Interest

85%

Examples:

  • The site occasionally has conflicts of interest, such as reporting on a new drug or treatment that a writer or their institution may have a financial stake in. However, this is rare and not a consistent issue.

Contradictions

90%

Examples:

  • There are occasional contradictions found in the articles, but they are usually related to recent research or new developments in medicine.

Deceptions

75%

Examples:

  • The site occasionally uses misleading headlines or presents information in a way that can be confusing or deceptive, such as implying a causal relationship between vaccines and long COVID without providing strong evidence to support this claim.

Recent Articles

  • GLP-1 Receptor Agonists Shift from Diabetes to Obesity Treatment: Implications and Trends

    GLP-1 Receptor Agonists Shift from Diabetes to Obesity Treatment: Implications and Trends

    Broke On: Tuesday, 23 July 2024 Since around 2020, GLP-1 receptor agonists (GLP-1 RAs) have seen a notable shift from treating type 2 diabetes to obesity in the US. This trend is driven by FDA approvals and the high prevalence of obesity, accounting for over 88% of new prescriptions being semaglutide. However, this shift raises concerns about potential drug shortages and disparities in access.
  • GLP-1 Drug Shortage: Diabetics Struggle to Obtain Necessary Dosages for Type 2 Diabetes Management

    GLP-1 Drug Shortage: Diabetics Struggle to Obtain Necessary Dosages for Type 2 Diabetes Management

    Broke On: Friday, 19 July 2024 A critical shortage of GLP-1 receptor agonist drugs, including Trulicity, leaves diabetics like Bob Dohman unable to obtain necessary dosages. The scarcity affects healthcare providers as they scramble for alternatives and secure limited supplies. Experts debate prioritizing patients for coverage and discuss strategies to address this pressing issue. Meanwhile, the choice between weight loss drugs Mounjaro and Ozempic should not be based on a single study.
  • New Study: Children's Secondhand Exposure to Nicotine from E-Cigarettes vs Tobacco Smoke - Comparative Findings

    New Study: Children's Secondhand Exposure to Nicotine from E-Cigarettes vs Tobacco Smoke - Comparative Findings

    Broke On: Friday, 12 July 2024 A new study in the Journal of the American Medical Association Network Open reveals that children living with e-cigarette users absorb 84% less nicotine through secondhand aerosols than those exposed to tobacco smoke. However, vaping still poses risks for children, particularly regarding lung development.
  • Five Countries Report Human Cases of Bird Flu: Latest Developments and Precautions

    Five Countries Report Human Cases of Bird Flu: Latest Developments and Precautions

    Broke On: Wednesday, 10 July 2024 Four dairy workers in the US and individuals from Mexico to China have tested positive for bird flu, marking the first known cases of cow-to-human transmission in the US. The virus has caused fatalities and outbreaks across multiple countries, including Vietnam, China, and Australia. The World Health Organization (WHO) remains on high alert for potential human cases and advises caution when handling raw meat or consuming undercooked meat products.
  • Semaglutide Linked to Increased Risk of NAION: Study Finds Hazard Ratios of 4.28 and 7.64 in Type 2 Diabetes and Overweight Populations, Respectively

    Semaglutide Linked to Increased Risk of NAION: Study Finds Hazard Ratios of 4.28 and 7.64 in Type 2 Diabetes and Overweight Populations, Respectively

    Broke On: Wednesday, 03 July 2024 A recent study published in JAMA Ophthalmology found that patients taking semaglutide, a medication for diabetes and obesity, had a significantly higher risk of developing Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), which can cause vision loss. The incidence rate was 4.28 times higher in type 2 diabetes patients and 7.64 times higher in overweight or obese patients taking semaglutide compared to non-GLP-1 RA medications.
  • 1 in 5 Americans Miss Out on Lung Cancer Screenings: Alarming Statistics and Solutions

    1 in 5 Americans Miss Out on Lung Cancer Screenings: Alarming Statistics and Solutions

    Broke On: Monday, 01 July 2024 Recent studies reveal that only 1 in 5 eligible Americans receive annual lung cancer screenings, despite recommendations for high-risk individuals. Compliance rates vary significantly by state and age, with older adults showing higher adherence. Medicaid expansion appears to correlate with higher screening rates. Innovative approaches like natural language processing and patient navigators can help increase awareness and accessibility to lung cancer screenings.
  • New Drug Tirzepatide Shows Promise in Treating Obstructive Sleep Apnea, Reducing Need for CPAP Devices by 40-50%

    New Drug Tirzepatide Shows Promise in Treating Obstructive Sleep Apnea, Reducing Need for CPAP Devices by 40-50%

    Broke On: Tuesday, 25 June 2024 New clinical trials show that Eli Lilly's tirzepatide injection, used for diabetes and weight loss, significantly reduces sleep disruptions in obstructive sleep apnea patients. Up to 50% of trial participants no longer needed CPAP devices and experienced lower C-reactive protein levels, systolic blood pressure, and an average weight loss of 18%-20%. The SURMOUNT-OSA studies mark a major advancement in OSA treatment.
  • Semaglutide: A Game-Changer in Weight Loss and Heart Health for Individuals with Cardiovascular Disease - SELECT Trial Results

    Semaglutide: A Game-Changer in Weight Loss and Heart Health for Individuals with Cardiovascular Disease - SELECT Trial Results

    Broke On: Sunday, 23 June 2024 Semaglutide, a weight-loss drug marketed as Wegovy or Ozempic, significantly reduces major adverse cardiovascular events (MACEs) by 20% for individuals with overweight or obesity and cardiovascular disease. The SELECT trial revealed that semaglutide users sustained weight loss for up to four years, dropped an average of 10% of their body weight, and showed improvements in heart health regardless of the amount lost. Semaglutide's benefits held up for all subgroups and normal A1c levels at baseline.
  • Urgent Action Needed: Experts Warn of Potential Pandemic from Bird Flu Virus Spreading Among Dairy Farms

    Urgent Action Needed: Experts Warn of Potential Pandemic from Bird Flu Virus Spreading Among Dairy Farms

    Broke On: Monday, 17 June 2024 Amidst growing concerns, the bird flu virus (H5N1) is spreading among dairy farms in the US, potentially mutating to infect people more easily and cause a new pandemic. Former CDC director Robert Redfield predicts a mortality rate between 25%-50%, warning that human cases may be overlooked due to limited testing. Authorities recommend preventative measures like hand washing and avoiding animal contact, while urging action to prevent potential dangers.
  • New Blood Test Predicts Parkinson's Disease Seven Years Before Symptoms Appear: A Game Changer in Early Detection

    New Blood Test Predicts Parkinson's Disease Seven Years Before Symptoms Appear: A Game Changer in Early Detection

    Broke On: Wednesday, 19 June 2024 A new blood test using artificial intelligence identifies eight biomarkers to predict Parkinson's disease up to seven years before symptoms appear, potentially revolutionizing diagnosis and treatment of this neurodegenerative disorder.